Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2021

Patel A, Hoda SA, Swistel AJ. Mammary myofibroblastoma in a male: A classic case. Breast J. 2021;27(2):181-182.

Pan PC, Pisapia DJ, Ramakrishna R, Schwartz TH, Pannullo SC, Knisely JP, et al. Outcomes following upfront radiation versus monitoring in atypical meningiomas: 16-year experience at a tertiary medical center. Neurooncol Adv. 2021;3(1):vdab094.

Jurgens EM, Ketas TJ, Zhao Z, Satlin MJ, Small CB, Sukhu A, et al. Serologic response to mRNA COVID-19 vaccination in lymphoma patients. Am J Hematol. 2021;96(11):E410-E413.

Sohani AR, Maurer MJ, Giri S, Pitcher B, Chadburn A, Said JW, et al. Biomarkers for Risk Stratification in Patients With Previously Untreated Follicular Lymphoma Receiving Anti-CD20-based Biological Therapy. Am J Surg Pathol. 2021;45(3):384-393.

Hansen G, Marino J, Wang Z-, Beavis KG, Rodrigo J, Labog K, et al. Clinical Performance of the Point-of-Care cobas Liat for Detection of SARS-CoV-2 in 20 Minutes: a Multicenter Study. J Clin Microbiol. 2021;59(2).

Anand P, Guillaumet-Adkins A, Dimitrova V, Yun H, Drier Y, Sotudeh N, et al. Single-cell RNA-seq reveals developmental plasticity with coexisting oncogenic states and immune evasion programs in ETP-ALL. Blood. 2021;137(18):2463-2480.

Väyrynen JP, Haruki K, Lau MC, Väyrynen SA, Zhong R, Costa AD, et al. The Prognostic Role of Macrophage Polarization in the Colorectal Cancer Microenvironment. Cancer Immunol Res. 2021;9(1):8-19.

Mukhopadhyay C, Yang C, Xu L, Liu D, Wang Y, Huang D, et al. G3BP1 inhibits Cul3SPOP to amplify AR signaling and promote prostate cancer. Nat Commun. 2021;12(1):6662.

Bhalla S, Bakouny Z, Schmidt AL, Labaki C, Steinharter JA, Tremblay DA, et al. Care disruptions among patients with lung cancer: A COVID-19 and cancer outcomes study. Lung Cancer. 2021;160:78-83.

Gill CM, Aktaş E, Alfouzan W, Bourassa L, Brink A, Burnham C-, et al. Elevated MICs of Susceptible Antipseudomonal Cephalosporins in Non-Carbapenemase-Producing, Carbapenem-Resistant Pseudomonas aeruginosa: Implications for Dose Optimization. Antimicrob Agents Chemother. 2021;65(11):e0120421.